Nexstim Receives NBS System 5 Order from New European Customer
10 July 2024 - 4:00PM
UK Regulatory
Nexstim Receives NBS System 5 Order from New European Customer
Press release, Helsinki, 10 July 2024
at 9 AM (EEST)
Nexstim Receives NBS System 5 Order from
New European Customer
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")
has received an order for an NBS System 5 through a distributor in
Europe. The end customer is acquiring the system primarily for
research purposes.
The Nexstim Navigated Brain Stimulation (NBS)
System 5 is indicated for non-invasive mapping of the primary motor
cortex of the brain to its cortical gyrus. The NBS System 5
provides information that may be used in the assessment of the
primary motor cortex for pre-procedural planning. The system
ordered also includes a therapy module, allowing the system to be
used for the treatment of major depression and chronic neuropathic
pain.
Mikko Karvinen, CEO of Nexstim, comments:
“Happy to announce this order and to welcome a new hospital
customer to our user community. We are proud to provide our
customers with access to an international research network, and to
have an active user base also when it comes to research use of our
systems.”
Further information is available on the
website www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for presurgical mapping of the speech and motor cortices
of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Press release_EU order_10072024_FINAL